Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

NCT02614872 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Transplantation, Lung Rejection

Interventions

DRUG: GLASSIA® and Institution standard of care (SOC)

Sponsor

Kamada, Ltd.